Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
Status:
Completed
Trial end date:
2018-08-29
Target enrollment:
Participant gender:
Summary
This phase 1-2 trial studies how well pembrolizumab with or without vismodegib works in
treating patients with skin basal cell cancer that has spread to other places in the body or
cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, are checkpoint
inhibitors that stimulate immune response. Vismodegib may stop the growth of tumor cells by
blocking signals needed for cell growth.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Anne Chang
Collaborators:
Merck Sharp & Dohme Corp. National Cancer Institute (NCI)